FDA Action Plan Released to Promote Competition, Affordability of Biosimilars
The FDA has released a Biosimilar Action Plan to promote competition and affordability across the market for biologic and biosimilar products.
All articles by Lauren Grygotis, Editor
Positive Phase 3 Data Announced for Ixekizumab in Ankylosing Spondylitis
Results from a phase 3 study show positive results for ixekizumab in patients with ankylosing spondylitis.
Etanercept, Infliximab, Adalimumab Biosimilars Show Similar Efficacy vs Reference Products in RA
A pooled analysis compared the efficacy and safety of anti-TNF biosimilars with their reference products.
Nonmedical Switching in Rheumatic Disease: An Interview With Allan Gibofsky, MD
Allan Gibofsky, MD, shares insight on the cost associated with nonmedical switching in patients with rheumatic diseases.
Erythrocyte-Bound C4d May Be Useful for SLE Disease Monitoring
Erythrocyte-bound C4d may be useful in monitoring systemic lupus erythematosus.
FDA Withdraws Draft Guidance in an Effort to Improve Efficiency of Biosimilar Development
The FDA has withdrawn draft guidance intended to provide advice regarding the evaluation of analytical similarity between a biosimilar and a reference product.
NSAID, TNFi Combination May Reduce Radiographic Progression in Ankylosing Spondylitis
Dose-related use of NSAIDs together with TNFi in patients with ankylosing spondylitis has a synergistic effect in slowing radiographic progression.
Baricitinib Shows Positive Results for Systemic Lupus Erythematosus in Phase 2 Study
Baricitinib 4 mg was safe and effective in patients with systemic lupus erythematosus.
Determining Elevated Thrombotic Risk in Systemic Lupus Erythematosus
Recent data from EULAR 2018 highlight the existence of thrombotic factors in systemic lupus erythematosus.
RA: MRI Values May Not Benefit Clinical, Radiographic Outcomes in Treat-to-Target Strategy
Researchers sought to determine whether a treat-to-target strategy based on MRI assessments targeting absence bone marrow edema would lead to improved clinical and radiographic outcomes.
-
Loading...
-
Loading...
Next post in EULAR 2018 Coverage
